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ABSTRACT The Xpert FluRSV Xpress Assay is a fast, automated in vitro diagnostic
test for qualitative detection and differentiation of inﬂuenza A and B viruses and respira-
tory syncytial virus (RSV) performed on the Cepheid GeneXpert Xpress System. The ob-
jective of this study was to establish performance characteristics of the Xpert FluRSV
Xpress Assay compared to those of the Prodesse ProFlu real-time reverse transcription-
PCR (RT-PCR) assay (ProFlu) for the detection of inﬂuenza A and B viruses as well as
RSV in a Clinical Laboratory Improvement Amendments (CLIA)-waived (CW) setting.
Overall, the assay, using fresh and frozen nasopharyngeal (NP) swabs, demonstrated
high concordance with results of the ProFlu assay in the combined CW and non-CW
settings with positive percent agreements (PPA) (100%, 100%, and 97.1%) and negative
percent agreements (NPA) (95.2%, 99.5%, and 99.6%) for inﬂuenza A and B viruses and
RSV, respectively. In conclusion, this multicenter study using the Cepheid Xpert FluRSV
Xpress Assay demonstrated high sensitivities and speciﬁcities for inﬂuenza A and B vi-
ruses and RSV in 60 min for use at the point-of-care in the CW setting.
KEYWORDS CLIA-waived, DNA polymerase, inﬂuenza, respiratory syncytial virus
Viral respiratory infections are leading causes of morbidity and mortality worldwide inyoung children, pregnant women, older adults, and patients with comorbidities (1–3).
Inﬂuenza virus and respiratory syncytial virus (RSV) remain common and burdensome
infections, especially at the extremes of age (4, 5). Rapid detection of these infections
enables timely and accurate management and potentially reduces transmission (6). Point-
of-care (POC) molecular tests have been shown to decrease overall time to receipt of test
results, testing costs, isolation times for hospitalized patients, and duration of hospitaliza-
tion (7–9). Improvements in turnaround times afforded by POC tests for viral respiratory
infections may also result in fewer unnecessary diagnostic imaging studies and antibiotic
treatments (1). Standards of care across various medical specialties reﬂect widespread
integration of molecular diagnostic testing. Although widely used, current rapid antigen
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diagnostic lateral ﬂow assays have variable, suboptimal test characteristics, as found by the
Centers for Disease Control and Prevention (10). Newer point-of-care molecular assays can
provide more accurate and timely results (11–13).
The Xpert FluRSV Xpress Assay is a fast, automated in vitro molecular diagnostic
test for qualitative detection and differentiation of inﬂuenza A and B (inﬂuenza A/B)
viruses and RSV performed on the Cepheid GeneXpert Xpress System. The Xpert
FluRSV Xpress Assay was designed for nasopharyngeal (NP) swab specimen testing by
nonlaboratory staff in a Clinical Laboratory Improvement Amendments (CLIA)-waived
(CW) setting. The instrument is highly automated and includes a touch-screen laptop
and step-by-step instructional videos for untrained users. The self-contained cartridges
are disposable, single-use devices containing all required reagents. Each module of the
instrument contains a syringe drive for dispensing ﬂuids within the cartridge, a soni-
cator for lysing cells, and a thermocycler for reverse transcription-PCR (RT-PCR). The
objective of this study was to establish performance characteristics of the Xpert
FluRSV Xpress Assay compared to those of the FDA-cleared commercially available
Prodesse ProFlu real-time RT-PCR assay (ProFlu) (Hologic, San Diego, CA, USA) for
the detection of inﬂuenza A and B viruses and RSV in a CLIA-waived setting.
MATERIALS AND METHODS
During the 2014-2015 respiratory virus season (September 2014 to March 2015), 12 sites from across
the United States participated in the study. All users were considered CW users throughout the study,
and they did not receive any trainer instruction or peer tutoring prior to the beginning of or during the
study. CW users reviewed only the written product instructions provided by Cepheid (quick reference
guide [QRG] and package insert) and were required to teach themselves how to install the instruments,
use the instruments, and run an assay. After the study, 2 of the 12 study sites were determined to be
non-CW sites because testing had been performed in moderately complex laboratories instead of
CLIA-waived settings. Samples were tested identically by users, regardless of setting. Patients with
respiratory infection symptoms were recruited from a spectrum of settings, including emergency
departments (EDs), outpatient and urgent care clinics, and hospital inpatient services. The study was
approved by central Institutional Review Boards (IRB) and local IRBs, depending on the particular site.
NP swab specimens in universal transport medium (UTM; Copan Diagnostics) were prospectively
collected from consenting/assenting participants during the 2014-2015 respiratory virus season. Patients
of all ages were eligible to participate in the study with appropriate consent and/or assent. Enrolled
patient ages ranged from younger than 5 years of age to older than 60 years of age. In addition,
deidentiﬁed, preselected frozen residual NP swab specimens supplemented the overall sample size to
achieve adequate numbers of positive samples for each of the viral targets. Inclusion criteria were signs
and symptoms of respiratory infection. Fresh NP swab specimens in UTM were stored at 2 to 8°C until
testing, which was required to be completed within 24 h of collection using the Xpert FluRSV Xpress
Assay. Specimens were stored at 2 to 8°C at the site until all testing was completed. Subsequently,
specimens were shipped to a centralized lab and stored at 2 to 8°C until testing by the ProFlu Assay,
as the reference test method, within 48 h of collection. Preselected frozen specimens in UTM were
thawed and stored at 2 to 8°C until testing with the Xpert FluRSV Xpress Assay, which was required to
be completed within 24 h of thawing. Specimens were stored at 2 to 8°C until all testing was complete.
For the preselected frozen specimens, inclusion criteria were the following: collection of specimens from
patients with signs and symptoms of respiratory infection, storage at 70°C or below, less than one
freeze-thaw cycle, and presence of sufﬁcient excess specimen for testing. Patients or samples previously
included in the study were excluded to avoid duplicate testing.
All Xpert FluRSV Xpress Assay testing and processing were performed within 24 h of prospective
specimen collection, utilizing three simple steps, as follows: (i) transfer the liquid sample to the cartridge via
the pipette supplied with the test kit, (ii) start the test, and (iii) read the result. Summary and detailed test
results, available in 60 min, were the following: positive or negative for inﬂuenza A and/or B virus and/or
RSV, no result/repeat test, or instrument error. The test was repeated one time if no result/repeat test or
instrument error was obtained on the initial test. If this recurred on the repeat test, the result was recorded
as a test failure. External controls (one negative and one positive for ﬂu A/B virus and one positive for RSV)
were tested daily prior to testing patient specimens on any given day that patient specimens were tested, by
each new operator prior to testing any patient specimens, and whenever a new lot of Xpert FluRSV Xpress
Assay reagents was received. The external-control results were veriﬁed as complete and valid prior to testing
any patient specimens. The results obtained from the Xpert FluRSV Xpress Assay were compared to those
obtained by the ProFlu assay, which was determined to be the appropriate reference standard based on
discussions between the FDA and Cepheid. Discordant results between the two assays were resolved by
bidirectional sequencing using primers other than those in the Xpert FluRSV Xpress Assay by an external
vendor. Data were summarized in tables of overall CW and non-CW sites and categorized by fresh versus
frozen specimens. Test characteristics were determined with associated 95% conﬁdence intervals (CIs),
including true positive (TP), true negative (TN), false positive (FP), false negative (FN), positive percent
agreement (PPA), negative percent agreement (NPA), and accuracy.
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Overall. A total of 2,553 patients and samples were included in the study, with 2,288
fresh prospective and 265 frozen specimens. Of the above, 2,435 specimens were retained
for analysis; 2,176 fresh and 259 frozen specimens met study criteria and had reportable
results for both the Xpert FluRSV Xpress Assay and the ProFlu assay. Patients included
1,406 female (57.7%) and 1,028 male (42.2%) patients, 422 (17.3%) of 5 years of age, 421
(17.3%) of 6 to 21 years of age, 1,302 (53.5%), of 22 to 59 years of age, 288 (11.8%) of 60
years of age, and 2 (0.1%) of unknown age. The patients were enrolled from the following
locations: 1,120 patients (46%) from the ED, 688 patients (28.3%) from the urgent care/
walk-in clinic, 565 (23.2%) outpatients, and 62 (2.5%) inpatients. The majority of specimens
tested (95.0%, 2,337/2,461) were successfully completed on the ﬁrst attempt by the Xpert
FluRSV Xpress Assay. A total of 115 of the 124 specimens were retested, of which 98
yielded valid results after a single retest. There were 17 specimens with invalid results on
retest which were excluded from the analyses. Overall, 1,743 (71.6%) of the results were
negative, and 692 (28.4%) were positive, as follows: 346 (14.2%) for inﬂuenza A virus, 172
(7.1%) for inﬂuenza B virus, 162 (6.7%) for RSV, 9 (0.4%) for inﬂuenza A virus and RSV, and
3 (0.1%) for inﬂuenza B virus and RSV. In aggregate, compared to results with the ProFlu
assay, the Xpert FluRSV Xpress Assay demonstrated high PPA, NPA, and accuracy values
for the detection of inﬂuenza A and inﬂuenza B viruses and RSV (Table 1). For the total
group, there were 111 discordant results that were resolved by bidirectional sequencing.
Following discordant resolution, the PPAs for inﬂuenza A virus, inﬂuenza B virus, and RSV
were 100% (95% CI, 98.89 to 100%), 100% (95% CI, 97.82 to 100%), and 97.73% (95% CI,
94.30 to 99.11%), respectively; the NPAs were 99.38% (95% CI, 98.94 to 99.64%), 99.87%
(95% CI, 99.61 to 99.95), and 99.91% (95% CI, 99.68 to 99.98%), respectively.
CLIA-waived setting. As described above, following completion of the study, two
sites were determined to have testing performed in a non-CW setting; therefore, the
subset of 10 CW site results are presented, as follows. A total of 2,080 of the NP swab
specimens (1,871 fresh and 209 frozen) met study criteria and were tested at CW sites
using the Xpert FluRSV Xpress Assay. Patient demographics were the following: 1,192
(57.3%) female patients, 887 (42.6%) male patients, 374 (18.0%) of 5 years of age, 375
(18.0%) of 6 to 21 of years, 1,094 (52.6%) of 22 to 59 years of age, and 237 (11.4%) of
TABLE 1 Demographics of enrolled subjects
Parameter




Female 1,406 (57.7) 1,192 (57.3)
Male 1,028 (42.2) 887 (42.6)
No response 1 (0.04) 1 (0.0)
Total 2,435 2,079
Age group
5 yr 422 (17.3) 374 (18.0)
6–21 yr 421 (17.3) 375 (18.0)
22–59 yr 1,302 (53.5) 1,094 (52.6)
60 yr 288 (11.8) 237 (11.4)
Unknown 2 (0.1) NAc
Total 2,435 2,080
Healthcare setting category
ED 1,120 (46.0) 793 (38.1)
Urgent care/walk-in clinic 688 (28.3) 688 (33.1)
Outpatient 565 (23.2) 550 (26.4)
Inpatient 62 (2.5) 49 (2.4)
Total 2,435 2,080
aCLIA-waived sites and non-CLIA-waived sites combined.
bCLIA-waived sites only.
cNA, not applicable.
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60 years of age. The patients were enrolled from the following locations: 793 (38.1%)
from the ED, 550 (26.4%) outpatients, 688 (33.1%) from an urgent care/walk-in clinic,
and 49 (2.4%) inpatients. Overall, 1,492 (71.7%) of the results were negative, and 588
(28.3%) were positive, as follows: 295 (14.2%) for inﬂuenza A virus, 144 (6.9%) for
inﬂuenza B virus, 138 (6.6%) for RSV, 9 (0.4%) for inﬂuenza A virus and RSV, and 2 (0.1%)
for inﬂuenza B virus and RSV. Compared to results with the ProFlu assay, the Xpert
FluRSV Xpress Assay demonstrated high PPA, NPA, and accuracy values for detection
of inﬂuenza A and inﬂuenza B viruses and RSV for both fresh and frozen samples in a
CW setting (Tables 2 and 3). For the CW group, there were 86 discordant results that
were resolved by bidirectional sequencing. Following discordant resolution, the PPAs
for inﬂuenza A and inﬂuenza B viruses and RSV were found to be 100% (95% CI, 98.7
to 100%), 100% (95% CI, 97.38 to 99.95%), and 98.01% (95% CI, 94.32 to 99.32%),
respectively. NPAs were 99.27% (95% CI, 98.76 to 99.57%), 99.85% (95% CI, 99.55 to
99.95%), and 99.95% (95% CI, 99.71 to 99.99%), respectively.
DISCUSSION
This multicenter study evaluated the Cepheid Xpert FluRSV Xpress Assay to detect
inﬂuenza A and B viruses as well as RSV in CW settings in the United States. Overall,
results of the assay were highly concordant with those of the ProFlu assay. This
ﬁnding is highlighted by the high PPAs and NPAs for inﬂuenza A and B viruses and RSV
on fresh prospective NP swabs in a CW setting by nonlaboratory users.
Prior studies have evaluated similar point-of-care molecular assays for inﬂuenza A
TABLE 2 Xpert FluRSV Xpress Assay performance versus ProFlu on NP swab specimens for CW sites and non-CW sites combined
Specimen type (n)a Target
No. of results by typeb
PPA (% [95% CI]) NPA (% [95% CI]) Accuracy (% [95% CI])TP FP TN FN
Fresh (2,176) Inﬂuenza A virus 250 101 1,825 0 100 (98.5–100) 94.8 (93.7–95.7) 95.4 (94.4–96.2)
Inﬂuenza B virus 63 10 2,103 0 100 (94.3–100) 99.5 (99.1–99.8) 99.5 (99.2–99.8)
RSV 125 8 2,039 4 96.9 (92.3–99.1) 99.6 (99.2–99.8) 99.4 (99.0–99.7)
Preselected frozen (259) Inﬂuenza A virus 0 4 255 0 NAc 98.5 (96.1–99.6) 98.5 (96.1–99.6)
Inﬂuenza B virus 100 2 157 0 100 (96.4–100) 98.7 (95.5–99.8) 99.2 (97.2–99.9)
RSV 40 1 217 1 97.6 (87.1–99.9) 99.5 (97.5–100) 99.2 (97.2–99.9)
Fresh and preselected frozen
combined (2,435)
Inﬂuenza A virus 250 105 2,080 0 100 (98.5–100) 95.2 (94.2–96.1) 95.7 (94.8–96.5)
Inﬂuenza B virus 163 12 2,260 0 100 (97.8–100) 99.5 (99.1–99.7) 99.5 (99.1–99.7)
RSV 165 9 2,256 5 97.1 (93.3–99.0) 99.6 (99.2–99.8) 99.4 (99.0–99.7)
aFresh, specimen prospectively collected from consented/assented subjects; preselected frozen, specimen deidentiﬁed, frozen, and known to be positive or negative
for a speciﬁc analyte. n, number of specimens.
bTP, true positive; FP, false positive; TN, true negative; FN, false negative.
cNA, not applicable.
TABLE 3 Performance of Xpert FluRSV Xpress versus ProFlu on NP swab specimens for CLIA-waived sites only
Specimen type (n)a Target
No. of results by typeb
PPA (% [95% CI]) NPA (% [95% CI])TP FP TN FN
Fresh (1,871) Inﬂuenza A virus 215 85 1,571 0 100 (98.3–100) 94.9 (93.7–95.9)
Inﬂuenza B virus 56 10 1,805 0 100 (93.6–100) 99.4 (99.0–99.7)
RSV 112 6 1,750 3 97.4 (92.6–99.5) 99.7 (99.3–99.9)
Preselected frozen (209) Inﬂuenza A virus 0 4 205 0 NAc 98.1 (95.2–99.5)
Inﬂuenza B virus 78 2 129 0 100 (95.4–100) 98.5 (94.6–99.8)
RSV 31 0 177 1 96.9 (83.8–99.9) 100 (97.9–100)
All NP swabs (2,080) Inﬂuenza A virus 215 89 1,776 0 100 (98.2–100) 95.2 (94.2–96.1)
Inﬂuenza B virus 134 12 1,934 0 100 (97.2–100) 99.4 (98.5–99.7)
RSV 143 6 1,927 4 97.3 (93.2–98.9) 99.7 (99.3–99.9)
aFresh, specimen prospectively collected from consented/assented subjects; preselected frozen, specimen deidentiﬁed, frozen, and known to be positive or negative
for a speciﬁc analyte. n, number of specimens.
bTP, true positive; FP, false positive; TN, true negative; FN, false negative.
cNA, not applicable.
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and B viruses (11, 13–18). Two of these reports of the Alere i Inﬂuenza A&B Assay
(Scarborough, ME, USA) demonstrated rapid results with high sensitivity within 15 min
and used nasal swabs, which are more comfortable for patients (11, 17). However, some
of these studies found lower speciﬁcities (62.5% for inﬂuenza A virus and 53.6% for
inﬂuenza B virus in one study and 85.6% for inﬂuenza A virus and 96.3% for inﬂuenza
B virus in another study) than those found in the present study (11, 15). Therefore, these
assays may require conﬁrmatory testing, depending on the clinical scenario; also, an
additional test would be needed to evaluate for RSV since that target is not included
in the Alere i Inﬂuenza A&B Assay. Similar to results of this study, the Cobas Inﬂuenza
A/B Assay (Roche Molecular Systems, Pleasanton, CA, USA) has reported high sensitiv-
ities (97.7% for inﬂuenza A virus and 98.6% for inﬂuenza B virus) as well as high
speciﬁcities (99.2% for inﬂuenza A virus and 99.4% for inﬂuenza B virus) for a 20-min CW
molecular assay; however, the assay also does not include RSV (13). In 2016, the Enigma
MiniLab assay for inﬂuenza A/B viruses and RSV (Enigma Diagnostics, Porton Down,
Salisbury, United Kingdom) was evaluated at a single-center study in the United
Kingdom with nonlaboratory personnel trained to use the molecular assay (12). That
platform provided results in 95 min with sensitivities of 81.8% for inﬂuenza A virus,
100% for inﬂuenza B virus, and 97.7% with the use of the reference standard, the
Luminex xTAG Respiratory Virus Panel (RVP) Fast, version 2 (Luminex, Austin, TX, USA)
(12). However, the Enigma test is not FDA cleared for CW testing, and speciﬁc training
was required as described in the study (12, 19).
Our study had limitations. As with any test, there were indeterminate results in the
present study; these were 0.7% overall and 1.1% in a CW setting. However, this rate
compares favorably to a similar assay for inﬂuenza A/B viruses and RSV (Enigma) of 5.6%
and to a CW inﬂuenza A/B virus test (Alere i) with a failure rate of 2 and 2.8% (11, 12).
Additionally, if conﬁrmatory testing is clinically indicated, then this will result in patient
care or cohorting delays. As currently designed, the assay is limited to three targets.
Future studies of these devices could be enhanced by performing all of the testing in
a CW environment. Additionally, future results may potentially vary by viral season,
given potentially shifting molecular targets as well as spectrum bias that may affect test
performance based on the case mix of the patients. As tested, the platform had one
module per system, which limited throughput. Having additional modules per unit
would be an enhancement in a CW setting. During the study period, results were
available in 60 min. Future enhancements could include reduction of turnaround
time to expedite decision making regarding disposition, cohorting, and potentially
antiviral treatment, all of which impact busy acute care settings.
Conclusion. The Cepheid Xpert FluRSV Xpress Assay performed on the GeneXpert
Xpress (GX-I) instrument was highly sensitive and speciﬁc compared with results
obtained from the ProFlu assay. These data indicate that the assay is highly suitable
and capable of facilitating reliable laboratory-quality PCR results within point-of-care
environments. The assay is easy to use and requires no training. The results are fast,
sensitive, and speciﬁc and can be used to inform real-time clinical decision making and
improve surveillance.
ACKNOWLEDGMENTS
For this study, Cepheid, Inc., funded the project for the institutions and authors.
Additionally, L.S.M. consults for Cepheid, Inc., and C.A.G. has received funding for
scientiﬁc lectures from Cepheid, Inc. We report no other conﬂicts.
REFERENCES
1. Dalziel SR, Thompson JM, Macias CG, Fernandes RM, Johnson DW,
Waisman Y, Cheng N, Acworth J, Chamberlain JM, Osmond MH, Plint A,
Valerio P, Black KJ, Fitzpatrick E, Newton AS, Kuppermann N, Klassen TP,
Pediatric Emergency Research Networks H1N1 Working Group. 2013.
Predictors of severe H1N1 infection in children presenting within Pedi-
atric Emergency Research Networks (PERN): retrospective case-control
study. BMJ 347:f4836. https://doi.org/10.1136/bmj.f4836.
2. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA,
Auinger P, Grifﬁn MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi
P. 2009. The burden of respiratory syncytial virus infection in young
Cepheid Assay for Inﬂuenza Virus and RSV Detection Journal of Clinical Microbiology
February 2018 Volume 56 Issue 2 e01237-17 jcm.asm.org 5
 o
n
 January 24, 2018 by W






children. N Engl J Med 360:588–598. https://doi.org/10.1056/NEJMoa
0804877.
3. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien
KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A,
Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA,
Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower
respiratory infections due to respiratory syncytial virus in young
children: a systematic review and meta-analysis. Lancet 375:1545–1555.
https://doi.org/10.1016/S0140-6736(10)60206-1.
4. Labella AM, Merel SE. 2013. Inﬂuenza. Med Clin North Am 97:621–645.
https://doi.org/10.1016/j.mcna.2013.03.001.
5. Brendish NJ, Schiff HF, Clark TW. 2015. Point-of-care testing for respira-
tory viruses in adults: the current landscape and future potential. J Infect
71:501–510. https://doi.org/10.1016/j.jinf.2015.07.008.
6. Chartrand C, Leeﬂang MM, Minion J, Brewer T, Pai M. 2012. Accuracy of
rapid inﬂuenza diagnostic tests: a meta-analysis. Ann Intern Med 156:
500–511. https://doi.org/10.7326/0003-4819-156-7-201204030-00403.
7. Rogers BB, Shankar P, Jerris RC, Kotzbauer D, Anderson EJ, Watson JR,
O’Brien LA, Uwindatwa F, McNamara K, Bost JE. 2015. Impact of a rapid
respiratory panel test on patient outcomes. Arch Pathol Lab Med 139:
636–641. https://doi.org/10.5858/arpa.2014-0257-OA.
8. Li-Kim-Moy J, Dastouri F, Rashid H, Khandaker G, Kesson A, McCaskill M,
Wood N, Jones C, Zurynski Y, Macartney K, Elliott EJ, Booy R. 2016. Utility
of early inﬂuenza diagnosis through point-of-care testing in children
presenting to an emergency department. J Paediatr Child Health 52:
422–429. https://doi.org/10.1111/jpc.13092.
9. Soto M, Sampietro-Colom L, Vilella A, Pantoja E, Asenjo M, Arjona R,
Hurtado JC, Trilla A, Alvarez-Martinez MJ, Mira A, Vila J, Marcos MA. 2016.
Economic impact of a new rapid PCR assay for detecting inﬂuenza virus
in an emergency department and hospitalized patients. PLoS One 11:
e0146620. https://doi.org/10.1371/journal.pone.0146620.
10. Centers for Disease Control and Prevention. 2016. Guidance for clinicians
on the use of rapid inﬂuenza diagnostic tests. Centers for Disease
Control and Prevention, Atlanta, GA. https://www.cdc.gov/ﬂu/pdf/
professionals/diagnosis/clinician_guidance_ridt.pdf.
11. Bell J, Bonner A, Cohen DM, Birkhahn R, Yogev R, Triner W, Cohen J,
Palavecino E, Selvarangan R. 2014. Multicenter clinical evaluation of the
novel Alere i Inﬂuenza A&B isothermal nucleic acid ampliﬁcation test. J
Clin Virol 61:81–86. https://doi.org/10.1016/j.jcv.2014.06.001.
12. Douthwaite ST, Walker C, Adams EJ, Mak C, Vecino Ortiz A, Martinez-Alier
N, Goldenberg SD. 2016. Performance of a novel point-of-care molecular
assay for detection of inﬂuenza A and B viruses and respiratory syncytial
virus (Enigma MiniLab) in children with acute respiratory infection. J Clin
Microbiol 54:212–215. https://doi.org/10.1128/JCM.02887-15.
13. Chen L, Tian Y, Chen S, Liesenfeld O. 2015. Performance of the Cobas
Inﬂuenza A/B Assay for rapid PCR-based detection of inﬂuenza com-
pared to Prodesse ProFlu and viral culture. Eur J Microbiol Immunol
(Bp) 5:236–245. https://doi.org/10.1556/1886.2015.00046.
14. Binnicker MJ, Espy MJ, Irish CL, Vetter EA. 2015. Direct detection of
inﬂuenza A and B viruses in less than 20 minutes using a commercially
available rapid PCR assay. J Clin Microbiol 53:2353–2354. https://doi.org/
10.1128/JCM.00791-15.
15. Chapin KC, Flores-Cortez EJ. 2015. Performance of the molecular Alere I
inﬂuenza A&B test compared to that of the Xpert ﬂu A/B assay. J Clin
Microbiol 53:706–709. https://doi.org/10.1128/JCM.02783-14.
16. Chiarella FC, Culebras E, Fuentes-Ferrer ME, Picazo JJ. 2016. Evaluation of
the Alere i Inﬂuenza A&B assay for rapid identiﬁcation of inﬂuenza A
and inﬂuenza B viruses. J Med Microbiol 65:456–461. https://doi.org/10
.1099/jmm.0.000249.
17. Nguyen Van JC, Camelena F, DahounM, Pilmis B, Mizrahi A, Lourtet J, Behillil
S, Enouf V, Le Monnier A. 2016. Prospective evaluation of the Alere i
Inﬂuenza A&B nucleic acid ampliﬁcation versus Xpert Flu/RSV. Diagn Mi-
crobiol Infect Dis 85:19–22. https://doi.org/10.1016/j.diagmicrobio.2015
.11.012.
18. Riazzo C, Perez-Ruiz M, Sanbonmatsu-Gamez S, Pedrosa-Corral I, Gutierrez-
Fernandez J, Navarro-Mari JM. 2015. Analytical performance of the Alere
i Inﬂuenza A&B assay for the rapid detection of inﬂuenza viruses. Enferm
Infecc Microbiol Clin 35:438–440. https://doi.org/10.1016/j.eimc.2015.10
.006.
19. Goldenberg SD, Edgeworth JD. 2015. The Enigma ML FluAB-RSV assay: a
fully automated molecular test for the rapid detection of inﬂuenza A, B
and respiratory syncytial viruses in respiratory specimens. Expert Rev
Mol Diagn 15:23–32. https://doi.org/10.1586/14737159.2015.983477.
Cohen et al. Journal of Clinical Microbiology
February 2018 Volume 56 Issue 2 e01237-17 jcm.asm.org 6
 o
n
 January 24, 2018 by W
ashington University in St. Louis
http://jcm.asm.org/
D
ow
nloaded from
 
